



22 October 2025

**Our Ref:** FOI 1294

Dear

**Freedom of Information Act 2000  
Information in relation to Haemophilia**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 21 July 2025. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Surgery & Elective, Maternity & Paediatric Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Manning**  
**Information Governance Officer**

**Q1. In the past 12 months [latest 12 months available], how many patients have been diagnosed with the each of the following conditions in your Trust:**

- **Haemophilia A**
- **Acquired Haemophilia A (AHA)**
- **Congenital Haemophilia A with inhibitors CHAwI)**

**Q2. In the last twelve months [latest 12 months available], how many pts with Haemophilia A, have been treated with each of the following products in your Trust:**

- **Factor Eight Inhibitor Bypass Activity (FEIBA)**
- **Hemlibra (standalone)**
- **Hemlibra in combination with NovoSeven RT**
- **Hemlibra in combination with Cevenfacta**
- **NovoSeven RT**
- **Obizur**
- **Cevenfacta**

**Q3. In the last twelve months [latest 12 months available], how many patients with Acquired Haemophilia A, have been treated with each of the following products in your Trust:**

- **Factor Eight Inhibitor Bypass Activity (FEIBA)**
- **NovoSeven RT**
- **Obizur**
- **Cevenfacta**

**Q4. In the last twelve months [latest 12 months available], how many pts with Congenital Haemophilia A with Inhibitors have been treated with each of the following products in your Trust?**

- **Factor Eight Inhibitor Bypass Activity (FEIBA)**
- **Hemlibra (standalone)**
- **Hemlibra in combination with NovoSeven RT**
- **Hemlibra in combination with Cevenfacta**
- **Hemlibra in combination with FEIBA**
- **Helimbra in combination with Factor VIII**
- **NovoSeven RT**
- **Obizur**
- **Cevenfacta**

A1-4. The information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice in respect of questions 1 to 4.

**Q5. What is the total Prothrombin Complex Concentrate usage in International Units (IUs) for your Trust over the last 12 months [latest 12 months available] for each of the products below in your Trust?**

- **Prothromplex**
- **Beriplex**
- **Octaplex**

A5. Please see Table 1.

Please note that the Trust commenced using a new Pathology system in October 2024, therefore the data provided is for the timeframe October 2024 to July 2025.

Table 1

<b>Product</b>	<b>Usage</b>
Prothromplex	Nil
Beriplx	Nil
Octaplex	239 000 IU

**Q6. Can you share the Prothrombin Complex Concentrate usage in International Units for your Trust in the last 12 months [latest 12 months available] within each of the departments, listed in table 1, and which PCC is used?**

- **Prothromplex**
- **Beriplex**
- **Octaplex**

- A6. There has been no usage of Prothromplex or Beriplex for any of the departments listed.

Please see Table 2 for the usage of Octaplex from October 2024 to July 2025.

Table 2

<b>Departments</b>	<b>Octaplex Usage</b>
Cardio Speciality	Nil
General Medicine	22,000 IU
General Surgery	31,500 IU
Haematology	Nil
Emergency Care	185,500 IU